CeraPedics (Lakewood, CO) developing products for the orthopedic bone substitute market announced the close of a $12.25M private equity financing from OrbiMed Advisors. The Company’s products utilize a proprietary small peptide called P-15™. This peptide has been identified to play a role in initiating the formation of bone. CeraPedics’ products may provide a safe, efficacious, [...]

• 159http://clsdf.com/2007/02/cerapedics-closes-12-25m-pe-financing/CeraPedics+Closes+%2412.25M+PE+Financing2007-03-01+05%3A14%3A00admin

CeraPedics, LLC was founded in 2000 to commercialize a proprietary technology for osteosynthetic bone substitute products and implant coatings that employ the Company’s small peptide P-15™ technology to facilitate bony fusion in orthopedic procedures. P-15 is a synthetic peptide analogous to the cell-binding domain of Type-I collagen. P-15 products create an ideal environment for bone [...]

• 26http://clsdf.com/2005/10/cerapedics-the-science-of-bone-repair/CeraPedics%3A+The+Science+of+Bone+Repair2005-10-10+19%3A06%3A00admin